Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML

Leukemia. 2019 Oct;33(10):2548-2553. doi: 10.1038/s41375-019-0504-y. Epub 2019 Jun 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Calgranulin A / genetics*
  • Calgranulin B / genetics*
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Sulfonamides / pharmacology*

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Calgranulin A
  • Calgranulin B
  • Proto-Oncogene Proteins c-bcl-2
  • S100A8 protein, human
  • S100A9 protein, human
  • Sulfonamides
  • venetoclax